**Anti-*Wolbachia* Drugs for Filariasis**

Kelly L. Johnston1,2, W. David Hong3, Joseph D. Turner1, Paul M. O’Neill3, Stephen A. Ward1, Mark J. Taylor1\*

1Centre for Neglected Tropical Diseases & Centre for Drugs & Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine

2 School of Life Sciences, Institute of Systems, Molecular & Integrative Biology,

 University of Liverpool.

3 Department of Chemistry, University of Liverpool

\* Correspondence: mark.taylor@lstmed.ac.uk (M. J. Taylor)

ORCID IDs:

Kelly L. Johnston: 0000-0002-5861-2646

W. David Hong: 0000-0002-0030-3007

Joseph D. Turner: 0000-0002-2185-5476

Paul M. O’Neill: 0000-0003-4338-0317

Stephen A. Ward: 0000-0003-2331-3192

Mark J. Taylor: 0000-0003-3396-9275

**Keywords:** *Wolbachia*, onchocerciasis, lymphatic filariasis, drug discovery

**Abstract**

The mutualistic association between *Wolbachia* endosymbionts and their filarial nematode hosts has been exploited as a validated drug target delivering macrofilaricidal outcomes. Limitations of existing antibiotics to scale-up have driven the search for new drugs, which are effective in shorter regimens of 7-days or less. Here, we review the last 14 years of anti-*Wolbachia* drug discovery by the A·WOL consortium, which has screened more than 2 million compounds, delivering thousands of hit compounds. Refined screening models integrated with robust PK/PD driven optimisation and selection strategies has delivered the first two drug candidates specifically designed to target *Wolbachia.* AWZ1066S and ABBV-4083 are currently progressing through clinical trials with the aim of delivering safe and effective macrofilaricides to support the elimination of onchocerciasis and lymphatic filariasis.

**Human filariasis: two neglected tropical diseases with chemotherapeutic challenges**

**Onchocerciasis** (see Glossary) and **lymphatic filariasis** (LF) are disabling diseases caused by parasitic filarial nematodes transmitted by insect vectors. With millions at risk, both diseases are classed as **neglected tropical diseases** (NTDs) and feature in the World Health Organisation’s (WHO) NTD roadmap for 2021-2030 [1]. Standard treatment for LF involves mass drug administration (MDA) strategies using the anthelmintics albendazole, ivermectin and diethylcarbamazine citrate (DEC), which, by targeting **microfilariae**, aim to interrupt transmission. Control programmes have made significant achievements over the last 20 years [2]. Double-drug treatment regimens (ivermectin plus albendazole or DEC plus albendazole) have been the mainstay for control programmes, but recent trials have demonstrated the superiority of a combination of all three drugs in clearing microfilariae and sterilising adult worms [3-6]. Given the potential to accelerate elimination, this triple combination of ivermectin, DEC and albendazole (IDA) is now being implemented in several countries [7]. However, barriers exist to using this approach as a treatment for LF in areas with overlapping incidence of onchocerciasis or another filarial disease, **loiasis**, and IDA is not currently recommended in such areas [8]. The MDA strategy for onchocerciasis relies on community-directed treatment with ivermectin (CDTI). DEC can cause severe adverse events (SAEs), including irreversible blindness and is contraindicated for onchocerciasis [9-11], while albendazole has no added benefit [12, 13]. Ivermectin can also cause serious adverse events in individuals with high *Loa loa* microfilarial loads [14], which can be fatal, highlighting the pressing need for alternative strategies to treat onchocerciasis [15]. Elimination of both onchocerciasis and LF are hindered by total reliance on **microfilaricidal** treatment regimens and the absence of a **macrofilaricidal** (adult-killing) treatment, which has been recognised as a critical requirement for onchocerciasis elimination by the WHO NTD roadmap [1]. Furthermore, the reliance on a single class of drug for MDA for onchocerciasis risks the development of resistance, with evidence of sub-optimal responses reported in Ghana and Cameroon consistent with this threat [16, 17]. This together with the widespread resistance to macrocyclic lactones in veterinary medicine including the filarial disease, heartworm [18, 19] re-enforces the need for alternative drugs to support the elimination of onchocerciasis and LF.

The causative agents of these diseases (*Onchocerca volvulus* for onchocerciasisand *Wuchereria bancrofti* and *Brugia malayi* for LF) each have a mutualistic symbiotic relationship with the obligate intracellular bacterium, *Wolbachia pipientis* [20, 21]. Disruption of this symbiosis impacts on the integrity of adult worms and leads to the permanent sterility and premature death of the normally long-lived adult worms (5-14 years) and has, therefore, become a focus of filariasis drug discovery efforts. Here, we review the last decade and a half of anti-*Wolbachia* drug discovery by the A·WOL consortium (i), the resulting outputs and future perspectives.

***Wolbachia*: a validated macrofilaricidal target**

*Antibiotics as treatments for human filariasis*

Several clinical trials using doxycycline, have demonstrated macrofilaricidal efficacy in human patients for both onchocerciasis and LF [22-25]. The therapeutic benefits of anti-wolbachial treatments are summarized in **Box 1**. An important advantage to the *anti-Wolbachia* approach is safety in *L. loa* endemic areas. *L. loa* lacks *Wolbachia* endosymbionts [26] and, therefore, is not affected by anti-*Wolbachia* treatments [25].

While community implementation of doxycycline treatment has been shown to be well-tolerated, feasible and effective in depleting *Wolbachia* [27, 28], can be implemented in restricted communities where existing strategies are failing [29, 30] (ii) and has been used as an end-game strategy in the Brazilian and Venezuelan Onchocerciasis Elimination Program for the Americas (OEPA) programmes [31], it is generally accepted that the 4-6 weeks of treatment and exclusion of pregnant women and children <8 are barriers to the scale-up of doxycycline as community-based anti-filarial therapy with associated compliance with anti-microbial resistance stewardship. New anti-*Wolbachia* drugs, that retain the efficacy characteristics of doxycycline, but are more easily and broadly implemented are needed.

*Anti-*Wolbachia *drug discovery: a focus for investment*

In 2007, the anti-*Wolbachia* (A·WOL) consortium was formed, funded by grants from the Bill & Melinda Gates Foundation awarded to the Liverpool School of Tropical Medicine (i). The primary aim of this global consortium, made up of academic and industrial partners, was to find new anti-*Wolbachia* drugs that overcome the barriers to doxycycline scale-up. A secondary aim was to optimise the regimens of registered drugs with anti-*Wolbachia* activity for use in more restricted settings. The first task was to create a Target Product Profile (TPP), which defines the desired characteristics of the new product in terms of its intended use in the target population and, ultimately, steers the drug discovery and development process. For onchocerciasis and LF, the A·WOL TPP included stipulations for any resulting drug to be available and efficacious in an oral formulation and require no more than 7 days treatment. Applicability for pregnant women and children <8 were also included as ‘ideal’ TPP criteria. The complete current A·WOL screening pipeline in presented in **Figure 1**.

**Primary screening assays: evolution of screening assay capacity**

*Assay development*

The A·WOL consortium brought industrial partners, with access to chemical libraries and technologies, together with academics with biological expertise to develop a robust drug screening assay. In the absence of a cell culture system for nematode *Wolbachia*, established cell cultures derived from *Wolbachia* infected mosquitoes were selected[32]. Initial experiments focused on determining the optimal conditions (including cell number, media replenishment requirements and assay duration) to establish a 96-well format assay with appropriate dynamic range between vehicle-treated and the ‘gold-standard’ doxycycline-treated cells. Using an established stably-infected C6/36(*w*AlbB) cell culture [33], various readouts were tested with a final selection of a 9-day assay endpoint, qPCR readout with toxicity assessed using a metabolism-based readout (CellTitre-Glo™) [34]. With the assay system defined, the first step in the A·WOL screening campaign was to test the complete human pharmacopoeia (2664 compounds) to identify registered drugs with anti-*Wolbachia* re-purposing potential [34]. This identified tetracyclines, rifamycins and the fluoroquinolone class of antibiotics as having anti-wolbachial activity. Further screening of focused libraries continued using this assay, including screening of a library of anti-infectives provided by Abbott (now Abbvie), that led to the discovery that the veterinary antibiotic, tylosin, had potent anti-*Wolbachia* efficacy. This prompted a medicinal chemistry programme that resulted in the development of TylAMac™ (ABBV-4083); the first designer semi-synthetic anti-*Wolbachia* drug [35, 36] (see **Translational status of A·WOL outputs** section).

*Scaling up: exploring chemical diversity*

The first large diversity library to be screened was made up of 10,000 compounds from the BioFocus SoftFocus libraries [37]. To complete this screening rapidly, improvements in capacity and throughput were required through altering qPCR reagents and optimising logistics. Screening was completed in less than 12 months and subsequent chemoinformatic analyses of the hits led to the discovery of six new chemotypes with activity against *Wolbachia* [37], one of which being the forerunner to the first fully synthetic A·WOL candidate AWZ1066S [38] (see **Translational status of A·WOL outputs** section).

The technological advances in microscopy-based multi-well systems provided an opportunity to revisit visualisation and quantification of *Wolbachia* within cells as a drug-screening assay. The development of a new assay using the Operetta high content automated imaging system (Perkin Elmer) with *Wolbachia*-infected cells involved stabilising cell-cell fluctuations in *Wolbachia* numbers through altering the culture medium, thus improving the signal window, as well as miniaturising the assay from 96-well to 384-well format. The readout was much simplified, using a simple DNA-stain, SYTO11, to visualise cell nuclei and *Wolbachia* and integrated Harmony software to determine infection levels. The signal window was also retained with a reduction in assay duration from 9 to 7 days. The resulting validated assay led to 25-fold improved throughput as well as the ability to generate EC50 curves [39]. These improvements facilitated progression of hits through hit-to-lead and lead optimisation workflows by, for example, allowing detailed **Structure Activity Relationship** (SAR) analyses to be conducted [35-38, 40].

*Industrial-scale A·WOL screening*

The improvements in throughput of the Operetta-based assay, as well as the implementation of simple robotics, facilitated larger-scale screening of 50,000+ compound libraries (including one gifted to the consortium by the Medicines for Malaria Venture, MMV) through this in-house screen. A partnership formed between the A·WOL consortium and the pharmaceutical company AstraZeneca led to an even further improved throughput by allowing access to their leading automation, screening technologies and expertise.

While the Operetta-based screen utilised a simple staining technique, throughput was hampered by the time taken to analyse the plates, a consequence of the magnification and number of fields of view required to achieve a robust signal to noise ratio. The assay developed through the shared knowledge and experience of A·WOL and AstraZeneca researchers simplified the readout from a ‘per-cell’ to ‘whole-well’ analysis, therefore accelerating data acquisition [41]. To achieve this, an immunofluorescence readout was developed, using the *Wolbachia*-specific antibody (anti-*Wolbachia* peptidoglycan-associated lipoprotein of *Brugia malayi*, *w*BmPAL) [42]. The industrial automation available at AstraZeneca allowed this more complex assay to be developed and validated [41] and subsequently used to screen AstraZeneca’s 1.3 million compound library in two months [43]. Subsequent chemoinformatic analyses prioritised approximately 6000 compounds for dose response screening resulting in 57 prioritised chemical clusters, with representatives ready to move through the pipeline [43].

**Orthogonal screening assays: prioritising hits**

*In vitro worm-based screening*

The A·WOL primary screening assay evolved over time to the point where in excess of 20,000 hits were discovered. Secondary screening assays involving *in vitro* worm-based assays using adult male *Onchocerca gutturosa* [44] or *B. malayi* [45] were included in earlier pipelines, but refinement of the *in vivo* model systems allowed these to be streamlined out [46]. However, the increased throughput of the primary assay, together with the accumulation of potency metrics from this assay, resulted in an accumulation of high potency hits. To prevent a bottleneck in the screening cascade, it became necessary to reintroduce a worm-based triage assay to prioritise compounds for entry into the available *in vivo* model systems (**Figure 1**). A 6-day *B. malayi* microfilarial (mf) assay [38, 43] was developed as a way to triage hits, with higher throughput than adult worm assays, by confirming that compounds (i) could penetrate the nematode cuticle to target nematode *Wolbachia* and (ii) did not have direct toxicity to the nematode. Potency was also measured for active compounds and could be factored into the screening prioritisation.

*Assessing dynamics of anti-*Wolbachia *activity*

A reduction in the duration of treatment is a core component of the TPP for a new anti-*Wolbachia* treatment. Comparing the time-kill dynamics of compounds, therefore, has potential to offer insight into which compounds are more likely to achieve this goal. By implementing a timed wash-out strategy (i.e. through washing off the compound after 24 h or 48 h of exposure) onto the standard microfilarial assay, the dynamics of anti-*Wolbachia* activity can be assessed. Importantly, compounds are compared using equi-potent concentrations (10 x EC50) in this assay to ensure that any differences in time-kill profile are not a result of differences in potency. When compared to antibiotics with activity against *Wolbachia* that are approved for human use (tetracyclines, rifamycins, fluoroquinolones), AWZ1066S and five chemotypes discovered *via* the AstraZeneca collaboration were demonstrated to have a more rapid kill profile in this assay [38, 43]. These six compounds reduce *Wolbachia* numbers significantly after only 24 h of treatment and can achieve equivalent reductions after 48 h to those achieved by doxycycline after 6 days. Not only does this offer hope for a reduced treatment regimen in the clinic, but would also indicate that, with these compounds, anti-*Wolbachia* drug discovery has shifted from operating purely in the bacteriostatic space and has discovered potentially bactericidal agents. Uncovering the mechanism of action of AWZ1066S, using chemical proteomic approaches is ongoing.

**Pre-clinical translational models**

Pharmacological evaluations of promising anti-*Wolbachia* candidates as anti-filarial agents requires assessment in the context of a whole animal physiological system. Laboratory drug testing has traditionally utilised the rodent, *Meriones unguiculatus* (Mongolian jird), which is naturally susceptible to a human sub-periodic isolate of *B. malayi*. Parasites establish long-term patent infections in either the lymphatics or the peritoneum, with persistent mf production circulating in the blood or contained within the peritoneal cavity, respectively [47-49]. Thus, these models closely emulate the life cycle traits and *Wolbachia* growth dynamics of human LF pathogens and are useful tools to predict *in vivo* anti-*Wolbachia* drug responses and concomitant parasitological efficacies against human LF infections: *B. malayi, B. timori* and *W. bancrofti*.

An alternative laboratory model adapted for drug screening utilises the *Wolbachia*-containing rodent filaria, *Litomosoides sigmodontis. L. sigmodontis* is a natural parasitic infection of cotton rats [50] and can be maintained in jirds with patent infections establishing in the pleural cavity surrounding the lungs and mf migrating into the circulation to develop parasitaemias. *L. sigmodontis* has also been selected *via* passage to survive for periods sufficient to complete its life-cycle within certain inbred strains of mice [51]. Advantages of this surrogate model are the increased convenience, throughput and reduced costs of using a smaller mouse host and faster growing rodent filaria, including reducing experimental anti-*Wolbachia* drug compound synthesis requirements (around 4-fold, considering weight difference between mice and jirds). More extensive murine pharmacokinetic data in public and industry domains is another advantage of undertaking filariasis testing within mice.

However, phylogenetic dissimilarities between *L. sigmodontis, Brugia spp,* and the medically important filarial pathogen*, O. volvulus,* risks a lack of translation when selecting drug candidates, particularly for onchocerciasis indications. In the context of anti-*Wolbachia* pharmacology, potential variability between *Litomosoides, Brugia* and *Onchocerca* include differences in the bioaccumulation of small molecules within *Wolbachia*-containing tissues (due to inherent differences in perfusion, active uptake, rate of metabolism or efflux of drug). Further intrinsic variability in type of *Wolbachia* (clade C in *Onchocerca vs* clade D in LF species and *Litomosoides*) [52] and nature of the symbiosis across different filariae [53] may influence anti-*Wolbachia* efficacy *via* variables such as drug target expression level, the relative sensitivity of the filaria to decline in *Wolbachia* populations, the growth rate of *Wolbachia,* and ultimate target *Wolbachia* biomass.

Due to limitations in current preclinical *in vivo* filarial drug screens, the A·WOL consortium developed novel mouse infection models of human filarial pathogens for anti-*Wolbachia* research and development. By identifying the mechanisms of innate and adaptive immune control of *B. malayi* in mice, it has been possible to establish chronic patent infections of this medically-important parasite in a range of transgenic mice deficient in facets of eosinophilic type-2 immunity [54, 55]. Due to global commercial availability and adaptability for humanisation, CB.17 Severe Combined Immunodeficient (SCID) mice were evaluated as a suitable long-term susceptible model of *B. malayi* infection and subsequently validated as a direct-acting or anti-*Wolbachia in vivo* drug screen using flubendazole or tetracycline antibiotics, respectively [56].

SCID mice were assessed for comparative susceptibility to *Onchocerca* adult infections*.* For this, we utilised the closely related cattle parasite, *Onchocerca ochengi,* which, by identification of naturally infected cattle from farms in the North of Cameroon, provides a convenient and abundant source of adult stages of the parasite. Three approaches were evaluated: development of adult infections from experimental inoculations of isolated infectious stage larvae, xenografts of isolated cattle nodules containing male and female worms or isolation and implantation of male *O. ochengi.* The latter approach proved reproducibly successful with approximately one third of the implanted male *O. ochengi* surviving a minimum of 6 weeks in the peritoneum of recipient SCID mice [56]. This model was subsequently validated using oral tetracycline and rifamycin antibiotics or flubendazole as the first small animal macrofilaricidal drug screen for the evaluation of drug candidates targeting *Onchocerca* [56-59].

Prior research has demonstrated that mf purified from cattle naturally infected with another *Onchocerca* cattle parasite, *O. lienalis,* can establish chronic microfilaridermias in SCID mice [60]. Following purifications of *Brugia* mf from jirds, we also could establish long-term circulating microfilaraemias in SCID mice. These microfilaraemic / microfilaridermic SCID mouse models are sensitive to the microfilaricide, ivermectin, provoking rapid, >90% decline in mf in the blood or skin two days post single dose treatment [56, 59, 60]. We therefore generated a microfilaraemic SCID mouse model of *L. loa* following mf purification from experimentally infected baboons or infected hypermicrofilaraemic loiasis individuals. *Loa* microfilaraemic mice were equally sensitive to the effects of single oral dose ivermectin with >90/98% depletions observed after two or seven days, respectively [61].

Thus, a ‘pan-filarial’ SCID mouse drug screening model has been established, susceptible to major human filarial genera of medical importance (*Brugia, Onchocerca, Loa*) with validated responses to reference antibiotics or filaricides (**Box 2**). This offers the advantage of testing drug candidates for anti-*Wolbachia* or direct macrofilaricidal efficacies and their selectivity to avoid rapid microfilaricidal toxicity whilst controlling for pharmacokinetic variabilities within a single SCID mouse strain. Via scrutinising efficacy sequentially against *B. malayi* adults, *O. ochengi* adult males and *L. loa* mf, the pan-filarial SCID mouse model has been implemented to evaluate five anti-filarial and nine anti-*Wolbachia* macrofilaricide candidates [57-59, 61-63] (**Figure 1**). The SCID models have provided robust **PK-PD** data supporting clinical selection of the anti-wolbachialsABBV-4083 and AWZ1066S as well as supporting the developmental pathway of the direct-acting clinical candidate, oxfendazole [61].

The pre-clinical screening models were also used to refine regimens of registered antibiotics including minocycline [62, 63], rifampicin [57, 58] and fluoroquinolones [64], in which combinations of anti-wolbachial drugs enabled shorter treatment regimes. An important, but unexpected outcome was the identification of drug synergy when combining anti-*Wolbachia* drugs with albendazole *in vivo.* The impact of this combinatorial drug synergy was to reduce treatment regimens necessary to mediate threshold anti-*Wolbachia* activity [65] and translated to deliver reduced dose time-frames in clinical trials against onchocerciasis [66] (**Figure 2**).

**Translational status of A·WOL outputs**

*ABBV-4083*

ABBV-4083 (**Figure 3**), also known as A-1574083 and TylAMac™, is the most advanced candidate in the clinical development pipeline – it has successfully completed Phase 1 trial and is advancing to a Phase 2 trial against onchocerciasis in a partnership with LSTM, Abbvie and DNDi (iii).

The original hits with the scaffold of ABBV-4083 were discovered in a focused macrolide library from the AbbVie antibiotic collection. Tylosin A (TylA) was identified as the most potent hit (another hit with lower potency is the analogue of TylA, tylosin B) *in vitro*. TylA is a well-established veterinary antibiotic with a good safety record, used mainly for the treatment of gram-positive bacterial infections in animals [67]. TylA demonstrated proof-of-concept *in vivo* efficacy in two filarial infection animal models when dosed through IP administration, but no activity when dosed orally. Hence improving permeability and oral bioavailability were the primary goals in the medicinal chemistry optimisation process. Masking the 2’- and 4”-hydroxyl groups as esters, carbamates and benzyl ethers in TylA was investigated and resulted in two lead compounds ABBV-4083 (benzyl ester at 4”-position) and A-1535469 (carbamate at 4”-position) showing marked improvement in oral PK profiles in the mouse or jird when comparing with TylA [36]. The two leads were assessed in several animal models, including *B. malayi*, *L. sigmodontis* and *O. ochengi* to determine their anti-*Wolbachia* efficacy *in vivo* and both showed excellent efficacy against *Wolbachia* (> 90% reduction) in these PD studies with 14-day oral dosing regimens (**Table 1**). In these animal models, when given human equivalent dose of tetracyclines, including doxycycline and minocycline, as positive controls, tetracyclines had to be dosed for at least 21 days to achieve similar levels of anti-*Wolbachia* activity (> 90% reduction). From these *in vivo* studies both TylA analogues demonstrated higher efficacy than tetracyclines over a shorter treatment period of 14 days. After extensive profiling comparing the two leads in terms of efficacy and PK profiles in various animal models, ABBV-4083 was selected as the preclinical candidate for development mainly due to its superior efficacy whilst A-1535469 remained as a strong backup compound. The effects of ABBV-4083 were further examined in pre-clinical models through additional parasitological end points, such as microfilarial production, number of adult worm recovery and worm embryonic stages with long wash-out periods after initial dosing. For example, in a longitudinal assessment of *L. sigmodontis* microfilaraemia, both ABBV-4083 (at 100 mg/kg, qd) and doxycycline (at 40 mg/kg, bid) were dosed for 14 days in jirds with established adult worm infection [68]. Although at the initial stage, both drugs showed effects in reducing the microfilaraemia when comparing with untreated animals at 10 weeks post-treatment, only the animals treated with ABBV- 4083 showed that the microfilaraemia continued to decline whilst the reduction of microfilaraemia in the doxycycline treatment group plateaued at week 11 – 16 post treatment. In fact, at week 15 – 16 post-treatment, the ABBV-4083 treated jirds showed no microfilariae in blood despite similar number of adult *L. sigmodontis* worms being recovered in all treated and untreated groups after 16 weeks post-treatment. Microscopic evaluation of the recovered female adult worms confirmed that significant decline in the number of intrauterine embryonic stages, e.g. morulae, coiled and stretched microfilariae in the ABBV-4083 treatment group in comparison to the untreated group [35].

In terms of safety profiling, one of the most important aspects of any newly developed anti-filarial drugs for consideration is their effect against the microfilaria of *L. loa* to avoid serious adverse events caused by direct microfilaricidal activity. This is a key advantage of anti-*Wolbachia* treatments due to the lack of *Wolbachia* in *L. loa*. ABBV-4083 was reported to show no effect on the motility of *L. loa* microfilariae at concentrations below 4 µM and with an IC50 = 23.3 µM *in vitro* which is far higher than the peak concentration (Cmax = 0.18 µM) the experimental drug can achieve at an efficacious dose (50 mg/kg) in jirds, which predicts that ABBV-4083 treatments would avoid *L. loa* serious adverse events. In addition to this, through a standard preclinical toxicology and safety assessment programme, ABBV-4083 was reported to have no adverse effect plasma concentrations in pre-clinical species higher than the required efficacious plasma concentrations in PD models [35]. The spectrum of activity of ABBV-4083 was investigated against a panel of other common bacterial species, which was similar to that of tylosin A and erythromycin, which will be taken into consideration for anti-microbial resistance stewardship.

*AWZ1066S*

AWZ1066S (**Figure 3**) is another anti-*Wolbachia* macrofilaricidal drug candidate that has completed its preclinical development successfully and is currently advancing to first-into-human Phase 1 clinical trial (iv). This candidate molecule was developed from hits identified from a phenotypic cell-based screening campaign incorporating a *Wolbachia*-infected *Aedes albopictus* cell line [C6/36 (*w*AlbB)] (see **Primary screening assays** section) [37]. A multi-parameter lead optimisation was performed with over 300 analogues synthesised and assessed for both anti-*Wolbachia* activity and drug metabolism and pharmacokinetics (DMPK) properties *in vitro*. In this process, the thienopyrimidine hit was modified to a quinazoline core and subsequently to an azaquinazoline scaffold from which the candidate AWZ1066 emerged, resolving the metabolic weakness associated with the original scaffold whilst improving potency. AWZ1066 was active against *Wolbachia* in the cell-based assay with an EC50 of 2.6 ± 0.5 nM and in an orthogonal secondary *in vitro* assay utilising mf of *B. malayi*, AWZ1066 with an EC50 of 150 nM whilst it had no effect on the viability and motility of the mf at up to the top testing concentration of 5 µM. The two enantiomers of AWZ1066, AWZ1066S and AWZ1066R, demonstrated minor differences in anti-*Wolbachia* potency *in vitro* with the (S)-isomer, AWZ1066S the more potent of the enantiomers in both *in vitro* assays (EC50s: Cell assay: 2.5 ± 0.4 nM vs. 14.4 ± 3.7 nM; mf assay: 122 nM vs. 408 nM). Extensive comparative analysis of the two enantiomers led to the selection of AWZ1066S, as the pre-clinical candidate based on superiority in terms of *in vitro* potency and *in vivo* efficacy [38].

A key criterion of the A·WOL TPP was a treatment regimen of no more than 7-days. In a number of nematode infection models, including *B. malayi* and *L. sigmodontis*, AWZ1066S was able to achieve the threshold reduction of *Wolbachia* (>90%) in 7-day treatment regimens (**Table 1**). Furthermore, the release of mf was completely prevented in 9/10 mice treated with AWZ1066S in the adult *B. malayi* SCID mouse model over the 6 weeks of observation post treatment. Similarly, in the adult *L. sigmodontis* BALB/c mouse model, after AWZ1066S treatment (50 mg/kg, bid, 7 days) the peripheral blood microfilaremia began to decline from 6 weeks post treatment and a state of amicrofilaraemia was evident from 14 weeks post-treatment and was sustained until the end of the experiment at 18 weeks post-treatment. All of these parasitology observations from PD studies clearly demonstrated the sustained effects on filarial embryogenesis and sterilisation after only 7-day treatment with AWZ1066S. The advantageous fast-kill character against *Wolbachia* of AWZ1066S was further demonstrated by a time-kill experiment against *Wolbachia* in the microfilaria of *B. malayi*. Comparing with other known anti-*Wolbachia* antibiotics, i.e. doxycycline, moxifloxacin and rifampicin, in this *in vitro* study, AWZ1066S was able to achieve the maximum *Wolbachia* depletion level after only 1 day exposure whilst the other drugs took 6 days exposure to reach the same level of depletion. Another important advantage of AWZ1066S is its high specificity against *Wolbachia* so that it would have minimum impact on the gut microbiota and the selection of resistance in clinical applications. AWZ1066S is the first (and, so far, only) macrofilaricidal drug candidate that is developed specifically against *Wolbachia* from the very beginning and this high specificity was confirmed by the lack of activity against a panel of clinically relevant bacteria [38].

*Other anti-Wolbachia leads*

In addition to these two clinical candidates, there are two other lead series of anti-*Wolbachia* chemotypes reported. One is a series of quinazolines, exemplified by one of the leads in the series, CBR490, that shows some chemical similarities with AWZ1066S [69]. CBR490 also showed some off-target toxicity in the CEREP panel safety screen and potential human Ether-à-go-go-Related Gene (hERG) liability [69]. Another series was derived from an antibiotic scaffold of pleuromutilin by the introduction of a boron-heterocycle moiety at the C(14)-position that is exemplified by one of the leads in the series, AN11251 [40]. The lead compounds in both series (CBR analogues and pleuromutilins) demonstrated potent activity in a number of *in vitro* and *in vivo* models against *Wolbachia* [70, 71]. However, their progression in the development pipeline is unclear at the moment.

*Mechanism of action*

The use of phenotypic screening at the core of the A·WOL drug discovery process successfully delivered candidates with specificity that was translatable through the pipeline. However, this strategy does not easily offer insights into how these new compounds exert their effects on *Wolbachia*. Given their endosymbiotic lifestyle, compounds could either target the bacteria directly, or affect host pathways that are important in the host-symbiont relationship. The fact that activity of the candidates is shared between *Wolbachia* in mosquito cells and nematode hosts argues against the latter possibility, although identifying the precise targets is an important aspect of drug discovery efforts. Due to the genetic intractability of *Wolbachia,* traditional genomics-based target identification approaches are unfeasible. Instead, a chemical proteomics approach is currently being utilised to identify the targets of AWZ1066S. Using the SAR knowledge gained via the lead optimisation process, photoaffinity labelling probes of AWZ1066S were designed and developed to perform affinity-purification of protein targets from live *Wolbachia*-infected cells. A short-list has been successfully generated [38] and future work is focused on confirming and validating the potential targets on the list, with the aim of rolling out this approach to other compounds.

**Concluding Remarks**

Within a decade and a half, the A·WOL consortium, with its partners, has created an industry quality translationally validated screening cascade from scratch (**Figure 1**). The assays are capable of screening millions of compounds in days and then triaging hits for lead identification, lead optimisation and candidate selection using disease relevant *in vitro* and *in vivo* pre-clinical infection models. The outputs of this endeavour are remarkable, delivering thousands of hit compounds and dozens of new chemical series, presumably including those with novel mechanisms of action, for onward investigation and development (**Figure 3**). Integrating the biological outputs with robust industry standard PK/PD driven optimisation and selection strategies has delivered the first two drugs ever developed specifically for filariasis to the point of human trials. This achievement through what is in effect a product development partnership (PDP) would be considered spectacular by any pharma industry norms.

The successes to date are really only the start of the journey. There is real optimism that AWZ1066S and/or ABBV-4083 will eventually achieve regulatory approval after further clinical evaluation, with multiple back-up options should they fail. The vast collection of hits series offers exciting opportunities not only for drug discovery but also as tool molecules to probe parasite/endosymbiont basic biology (see **Outstanding Questions**).

After more than 10 years investment from many contributors to the A·WOL initiative we are in a strong position, subject to continued financial support for the sector, to actually deliver drugs that fully meet the TPP that was developed to deliver elimination of these important NTDs.

**Acknowledgment**

We thank all those people associated with the A·WOL consortium. Our External Scientific Advisory Committee and Clinical Trial Data Monitoring and Ethics Committee. Programme managers from B&MGF: Ken Duncan, Richard Elliot, Tom Kanyok, Doug Holtzman. Our pharma industry partners; **Abbvie:** Dale Kempf**,** Tom von Geldern, Kennan Marsh, Howard Morton, Robert Carr et al.; **Anacor:** Eric Easom, Jake Plattner, Dickon Alley, Bob Jacobs et al.; **AstraZeneca:** Catherine Bardelle,Ulf Börjesson**,** Roger Clark, Matthew Collier**,** Paul Harper**,** Darren Plant**,** Helen Plant, Kirsty Rich, Mark Wigglesworth, Peter Webborn, Stefan Kavanagh et al.**; Eisai:** Farid Benayoud, Amy Siu**,** Motohiro Shiotani**,** Fabian Gusovsky et al.**; Forma Therapeutics:** Ralf Altmeyer, Indira Umareddy; **New England Biolabs**: Clotilde Carlow, Jeremy Foster, Sanjay Kumar, Barton Slatko et al.; **WuXi:** Luqing Huang, Yusong Zhu. Our academic partners; **Imperial College:** Maria-Gloria Basanez, Martin Walker, Ed Tate; **Kwame Nkrumah University of Science and Technology:** Alexander Yaw Debrah, Ohene Adjei, et al.; **Northwick Park Institute for Medical Research:** Simon Townson et al.; **RETOFDE & University of Buea:** Desmond Akumtoh, Patrick Chounna, Valerine Chunda, Fanny Fombad, Narcisse Gandjui, Tayong Kwenti, Haelly Metuge, Bertrand Ndzeshang, Abdel Njouendou, Samuel Wanji et al.; **TRS labs:** John McCall et al.; **University of Bonn:** Achim Hoerauf, Marc Hubner, Ute Klarmann-Schultz, Sabine Mand, Ken Pfarr, Sabine Specht (now DNDi) et al.; **University of California, Santa Cruz:** Frederic Landmann, Laura Serbus, William Sullivan et al.; **DNDi:** Laurant Fraisse, Frédéric Monnot, Sabine Specht et al Our teams at **LSTM & University of Liverpool:** Ghaith Aljayyoussi,John Archer,Neil Berry,Jaclyn Bibby, Christina Bronowski,Andy Cassidy,Sitthivut Charoensutthivarakul,Rachel Clare,Darren Cook,Susie Crossman,Jill Davies,Louise Ford,Amber Fanthome,Joanne Gamble, Peter Gibbons,Megan Goddard**,** Phil Gould,Ana Guimaraes,Alice Halliday,Susan Harris,Laura Hayward, Phil Inglesby, Susan Jones,Nancy Khammo,Shirley Leung,Qie Li,Monika Lisauskaite, Amy Marriott,Paul McGillan,Gemma Molyneux, Emma Murphy,Laura Myhill, Gemma Nixon,Nicolas Pionnier, Shannon Quek,Raman Sharma,Hanna Sjoberg,Andrew Steven,Francesca Tamarozzi, Hayley Tyrer, Vera Unwin,Denis Voronin,Elly Wallis,Simon Wagstaff,David Waterhouse, Yang Wu,Anfal Yousef.

The A·WOL consortium is supported by grants from the Bill & Melinda Gates Foundation awarded to the Liverpool School of Tropical Medicine (OPP1054324, OPP1045261, OPP39284, OPP1040992, OPP1087064, OPP1119043, OPP10867). This work was also supported by Grant GHIT-RFP-2013-002 from the Global Health Innovative Technology (GHIT) Fund. Funding was also received from the Medical Research Council, including grant MR/R025401/1 and Confidence in Concept funding via the Tropical Infectious Disease Consortium, as well as from an Engineering and Physical Sciences Research Council doctoral programme PhD studentship for Miss Monika Lisauskaite.

**Declaration of Interests**

The authors declare no competing interests.

**Resources**

i https://awol.lstmed.ac.uk/

ii <https://www.sightsavers.org/blogs/2017/06/test-and-treat-tackling-river-blindness-in-cameroon/>

iii https://dndi.org/research-development/portfolio/abbv-4083/

iv <https://www.ghitfund.org/investment/portfoliodetail/detail/155/en>

**References**

1 World Health Organization (2020) Ending the neglect to attain the Sustainable Development Goals – A road map for neglected tropical diseases 2021–2030. *Geneva: World Health Organization*

2 Malecela, M.*, et al.* (2021) Two decades of public health achievements in lymphatic filariasis (2000-2020): reflections, progress and future challenges. *Int. Health* 13, S1-S2

3 Bjerum, C.M.*, et al.* (2020) Efficacy and safety of a single dose of ivermectin, diethylcarbamazine, and albendazole for treatment of lymphatic filariasis in Cote d'Ivoire: an open-label randomized controlled trial. *Clin. Infect. Dis.* 71, E68-E75

4 King, C.L.*, et al.* (2018) A trial of a triple-drug treatment for lymphatic filariasis. *New Engl. J. Med.* 379, 1801-1810

5 King, C.L.*, et al.* (2020) Single-dose triple-drug therapy for *Wuchereria bancrofti*-5-Year follow-up. *New Engl. J. Med.* 382, 1956-1957

6 Thomsen, E.K.*, et al.* (2016) Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. *Clin. Infect. Dis.* 62, 334-341

7 Weil, G.J.*, et al.* (2021) A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery. *Int. Health* 13, S60-S64

8 World Health Organization (2017) Alternative mass drug administration regimens to eliminate lymphatic filariasis. *Geneva: World Health Organization*

9 Bird, A.C.*, et al.* (1979) Visual loss during oral diethylcarbamazine treatment for onchocerciasis. *Lancet* 2, 46

10 Bird, A.C.*, et al.* (1980) Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. *Br. J. Ophthalmol.* 64, 191-200

11 Dadzie, K.Y.*, et al.* (1987) Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis. *Br. J. Ophthalmol.* 71, 78-85

12 Awadzi, K.*, et al.* (2003) The co-administration of ivermectin and albendazole safety, pharmacokinetics and efficacy against *Onchocerca volvulus*. *Ann. Trop. Med. Parasit.* 97, 165-178

13 Batsa Debrah, L.*, et al.* (2020) Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for the treatment of onchocerciasis: a randomized, open-label, clinical trial. *Clin. Infect. Dis.* 71, 933-943

14 Boussinesq, M.*, et al.* (2003) Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. *Filaria J.* 2 Suppl 1, S4

15 Boussinesq, M.*, et al.* (2018) Alternative treatment strategies to accelerate the elimination of onchocerciasis. *Int. Health* 10, i40-i48

16 Doyle, S.R.*, et al.* (2017) Genome-wide analysis of ivermectin response by *Onchocerca volvulus* reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity. *PLoS Negl. Trop. Dis.* 11, e0005816

17 Osei-Atweneboana, M.Y.*, et al.* (2011) Phenotypic evidence of emerging ivermectin resistance in *Onchocerca volvulus*. *PLoS Negl. Trop. Dis.* 5, e998

18 Prichard, R.K. and Geary, T.G. (2019) Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance. *Int. J. Parasitol. Drugs Drug. Resist.* 10, 69-83

19 Turner, J.D.*, et al.* (2020) Novel anti-*Wolbachia* drugs, a new approach in the treatment and prevention of veterinary filariasis? *Vet. Parasitol.* 279, 109057

20 Slatko, B.E.*, et al.* (2010) The *Wolbachia* endosymbiont as an anti-filarial nematode target. *Symbiosis* 51, 55-65

21 Tamarozzi, F.*, et al.* (2011) Onchocerciasis: the role of *Wolbachia* bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment. *Clin. Microbiol. Rev.* 24, 459-468

22 Hoerauf, A.*, et al.* (2008) *Wolbachia* endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. *Med. Microbiol. Immunol.* 197, 295-311

23 Hoerauf, A.*, et al.* (2009) Efficacy of 5-week doxycycline treatment on adult *Onchocerca volvulus*. *Parasitol. Res.* 104, 437-447

24 Taylor, M.J.*, et al.* (2005) Macrofilaricidal activity after doxycycline treatment of *Wuchereria bancrofti*: a double-blind, randomised placebo-controlled trial. *Lancet* 365, 2116-2121

25 Turner, J.D.*, et al.* (2010) Macrofilaricidal activity after doxycycline only treatment of *Onchocerca volvulus* in an area of *Loa loa* co-endemicity: a randomized controlled trial. *PLoS Negl. Trop. Dis.* 4, e660

26 McGarry, H.F.*, et al.* (2003) Evidence against *Wolbachia* symbiosis in *Loa loa*. *Filaria J.* 2, 9

27 Tamarozzi, F.*, et al.* (2012) Long term impact of large scale community-directed delivery of doxycycline for the treatment of onchocerciasis. *Parasit. Vectors* 5, 53

28 Wanji, S.*, et al.* (2009) Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon. *Parasit. Vectors* 2, 39

29 Forrer, A.*, et al.* (2021) Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon. *BMJ Glob. Health* 6, e003248

30 Wanji, S.*, et al.* (2019) Implementation of test-and-treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co-endemicity: the COUNTDOWN consortium multi-disciplinary study protocol. *Parasit. Vectors* 12, 574

31 World Health Organization (2019) Progress in eliminating onchocerciasis in the WHO Region of the Americas: doxycycline treatment as an end-game strategy. *Weekly Epidemiological Record* 94, 413-424

32 Fenollar, F.*, et al.* (2003) *Wolbachia pipientis* growth kinetics and susceptibilities to 13 antibiotics determined by immunofluorescence staining and real-time PCR. *Antimicrob. Agents Chemother.* 47, 1665-1671

33 Turner, J.D.*, et al.* (2006) *Wolbachia* endosymbiotic bacteria of *Brugia malayi* mediate macrophage tolerance to TLR- and CD40-specific stimuli in a MyD88/TLR2-dependent manner. *J. Immunol.* 177, 1240-1249

34 Johnston, K.L.*, et al.* (2014) Repurposing of approved drugs from the human pharmacopoeia to target *Wolbachia* endosymbionts of onchocerciasis and lymphatic filariasis. *Int. J. Parasitol. Drugs Drug Resist.* 4, 278-286

35 Taylor, M.J.*, et al.* (2019) Preclinical development of an oral anti-*Wolbachia* macrolide drug for the treatment of lymphatic filariasis and onchocerciasis. *Sci. Transl. Med.* 11, eaau2086

36 von Geldern, T.W.*, et al.* (2019) Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-*Wolbachia* and anti-filarial activity. *PLoS Negl. Trop. Dis.* 13, e0007159

37 Johnston, K.L.*, et al.* (2017) Identification and prioritization of novel anti-*Wolbachia* chemotypes from screening a 10,000-compound diversity library. *Sci. Adv.* 3, eaao1551

38 Hong, W.D.*, et al.* (2019) AWZ1066S, a highly specific anti-*Wolbachia* drug candidate for a short-course treatment of filariasis. *Proc. Natl. Acad. Sci. U. S. A.* 116, 1414-1419

39 Clare, R.H.*, et al.* (2015) Development and validation of a high-throughput anti-*Wolbachia* whole-cell screen: a route to macrofilaricidal drugs against onchocerciasis and lymphatic filariasis. *J. Biomol. Screen.* 20, 64-69

40 Jacobs, R.T.*, et al.* (2019) Boron-pleuromutilins as anti- *Wolbachia* agents with potential for treatment of onchocerciasis and lymphatic filariasis. *J. Med. Chem.* 62, 2521-2540

41 Clare, R.H.*, et al.* (2019) Development of a high-throughput cytometric screen to identify anti- *Wolbachia* compounds: the power of Public-Private Partnership. *SLAS Discov.* 24, 537-547

42 Turner, J.D.*, et al.* (2009) *Wolbachia* lipoprotein stimulates innate and adaptive immunity through Toll-like receptors 2 and 6 to induce disease manifestations of filariasis. *J. Biol. Chem.* 284, 22364-22378

43 Clare, R.H.*, et al.* (2019) Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides. *Nat. Commun.* 10, 11

44 Townson, S.*, et al.* (2006) *Onchocerca* parasites and *Wolbachia* endosymbionts: evaluation of a spectrum of antibiotic types for activity against *Onchocerca gutturosa* *in vitro*. *Filaria J.* 5, 4

45 Johnston, K.L.*, et al.* (2010) Lipoprotein biosynthesis as a target for anti-*Wolbachia* treatment of filarial nematodes. *Parasit. Vectors* 3, 99

46 Johnston, K.L.*, et al.* (2014) Overcoming the challenges of drug discovery for neglected tropical diseases: the A.WOL experience. *J. Biomol. Screen.* 19, 335-343

47 Ash, L.R. and Riley, J.M. (1970) Development of subperiodic *Brugia malayi* in the jird, *Meriones unguiculatus*, with notes on infections in other rodents. *J. Parasitol.* 56, 969-973

48 Ash, L.R. and Riley, J.M. (1970) Development of *Brugia pahangi* in the jird, *Meriones unguiculatus*, with notes on infections in other rodents. *J. Parasitol.* 56, 962-968

49 McCall, J.W.*, et al.* (1973) Mongolian jirds (*Meriones unguiculatus*) infected with *Brugia pahangi* by the intraperitoneal route: a rich source of developing larvae, adult filariae, and microfilariae. *J. Parasitol.* 59, 436

50 Williams, R.W. and Brown, H.W. (1946) The transmissions of *Litomosoides carinii*, filariid parasite of the cotton rat, by the tropical rat mite, *Liponyssus bacoti*. *Science* 103, 224

51 Petit, G.*, et al.* (1992) Maturation of the filaria *Litomosoides sigmodontis* in BALB/c mice; comparative susceptibility of nine other inbred strains. *Ann. Parasitol. Hum. Comp.* 67, 144-150

52 Lefoulon, E.*, et al.* (2020) Diminutive, degraded but dissimilar: *Wolbachia* genomes from filarial nematodes do not conform to a single paradigm. *Microb. Genom.* 6

53 Gill, A.C.*, et al.* (2014) Iron necessity: the secret of *Wolbachia*'s success? *PLoS Negl. Trop. Dis.* 8, e3224

54 Pionnier, N.*, et al.* (2020) Eosinophil-mediated immune control of adult filarial nematode infection can proceed in the absence of IL-4 receptor signaling. *J. Immunol.* 205, 731-740

55 Turner, J.D.*, et al.* (2018) Interleukin-4 activated macrophages mediate immunity to filarial helminth infection by sustaining CCR3-dependent eosinophilia. *PLoS Pathog.* 14, e1006949

56 Halliday, A.*, et al.* (2014) A murine macrofilaricide pre-clinical screening model for onchocerciasis and lymphatic filariasis. *Parasit. Vectors* 7, 472

57 Aljayyoussi, G.*, et al.* (2017) Short-course, high-dose rifampicin achieves *Wolbachia* depletion predictive of curative outcomes in preclinical models of lymphatic filariasis and onchocerciasis. *Sci. Re.p* 7, 210

58 Aljayyoussi, G.*, et al.* (2018) Author Correction: Short-course, high-dose rifampicin achieves *Wolbachia* depletion predictive of curative outcomes in preclinical models of lymphatic filariasis and onchocerciasis. *Sci. Rep.* 8, 1384

59 Sjoberg, H.T.*, et al.* (2019) Short-course, oral flubendazole does not mediate significant efficacy against *Onchocerca* adult male worms or *Brugia* microfilariae in murine infection models. *PLoS Negl. Trop. Dis.* 13, e0006356

60 Folkard, S.G.*, et al.* (1997) Protective responses against skin-dwelling microfilariae of *Onchocerca lienalis* in severe combined immunodeficient mice. *Infect. Immun.* 65, 2846-2851

61 Pionnier, N.P.*, et al.* (2019) Mouse models of *Loa loa*. *Nat. Commun.* 10, 1429

62 Sharma, R.*, et al.* (2018) Corrigendum: Minocycline as a re-purposed anti-*Wolbachia* macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. *Sci. Rep.* 8, 46934

63 Sharma, R.*, et al.* (2016) Minocycline as a re-purposed anti-*Wolbachia* macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. *Sci. Rep.* 6, 23458

64 Specht, S.*, et al.* (2018) Combinations of registered drugs reduce treatment times required to deplete *Wolbachia* in the *Litomosoides sigmodontis* mouse model. *PLoS Negl. Trop. Dis.* 12, e0006116

65 Turner, J.D.*, et al.* (2017) Albendazole and antibiotics synergize to deliver short-course anti-*Wolbachia* curative treatments in preclinical models of filariasis. *Proc. Natl. Acad. Sci. U. S. A.* 114, E9712-E9721

66 Klarmann-Schulz, U.*, et al.* (2017) Comparison of doxycycline, minocycline, doxycycline plus albendazole and albendazole alone in their efficacy against onchocerciasis in a randomized, open-label, pilot trial. *PLoS Negl. Trop. Dis.* 11, e0005156

67 Arsic, B.*, et al.* (2018) 16-membered macrolide antibiotics: a review. *Int. J. Antimicrob. Agents* 51, 283-298

68 Hubner, M.P.*, et al.* (2019) *In vivo* kinetics of *Wolbachia* depletion by ABBV-4083 in *L. sigmodontis* adult worms and microfilariae. *PLoS Negl. Trop. Dis.* 13, e0007636

69 Bakowski, M.A.*, et al.* (2019) Discovery of short-course antiwolbachial quinazolines for elimination of filarial worm infections. *Sci. Transl. Med.* 11

70 Ehrens, A.*, et al.* (2020) *In vivo* efficacy of the boron-pleuromutilin AN11251 against *Wolbachia* of the rodent filarial nematode *Litomosoides sigmodontis*. *PLoS Negl. Trop. Dis.* 14, e0007957

71 Hubner, M.P.*, et al.* (2020) Short-course quinazoline drug treatments are effective in the *Litomosoides sigmodontis* and *Brugia pahangi* jird models. *Int. J. Parasitol. Drugs Drug. Resist.* 12, 18-27

72 Debrah, A.Y.*, et al.* (2007) Macrofilaricidal effect of 4 weeks of treatment with doxycycline on *Wuchereria bancrofti*. *Trop. Med. Int. Health* 12, 1433-1441

**Glossary**

**Loiasis:** a disease caused by infection with the filarial nematode *Loa loa*, also known as African eye worm. The infective larvae of these parasites are transmitted by deer flies and develop to become adult worms that reside in the subcutaneous tissues. First-stage larvae (microfilariae) are released by females which can enter the blood to be taken up by deer flies, where they develop into infective larvae to complete the life cycle. Symptoms can include localised “Calabar” swellings and eye worm. *L. loa* nematodes do not contain *Wolbachia* bacteria.

**Lymphatic filariasis (LF):** a disease caused by infection with the filarial nematodes *Wuchereria bancrofti,* *Brugia malayi* and *Brugia timori*. The infective larvae of these parasites are transmitted by mosquitoes and develop to become adult worms that reside in the lymphatics. First-stage larvae (microfilariae) are released by females into the blood to be taken up by mosquitoes, where they develop into infective larvae to complete the life cycle. Pathology, generally caused by inflammation in response to the death of adult worms, can involve severe swelling of the limbs, breasts and genitals. Nematodes that cause lymphatic filariasis contain *Wolbachia* bacteria.

**Microfilariae:** first-stage larvae of filarial nematodes.

**Macrofilaricidal:** a descriptive term for a drug or compound that kills adult filarial nematodes.

**Microfilaraemia:** the presence of microfilariae in the blood.

**Microfilaricidal:** a descriptive term for a drug or compound that kills microfilariae.

**Microfilaridermia:** the presence of microfilariae in the skin.

**Neglected Tropical Diseases:** a diverse group of 20 communicable diseases, defined by the WHO, which affect more than one billion people in tropical and sub-tropical regions.

**Onchocerciasis:** a disease caused by infection with the filarial nematode *Onchocerca volvulus*. The infective larvae of these parasites are transmitted by black flies and develop to become adult worms that reside within nodules in subcutaneous and deeper tissues. First-stage larvae (microfilariae) are released by females into the skin to be taken up by black flies, where they develop into infective larvae to complete the life cycle. Microfilariae can also migrate to the eye. Pathology, generally caused by inflammation in response to dead or dying microfilariae, is skin disease (onchodermatitis) and visual impairment leading to blindness (‘river blindness’). *O. volvulus* nematodes contain *Wolbachia* bacteria.

**Pharmacokinetic-Pharmacodynamic (PK-PD):** PK-PD modelling/analysis. Integration of pharmacokinetic information (how the drug is absorbed, distributed, metabolised and excreted) with pharmacodynamic information (the effects of the drug on the infection and the body) to understand dose and effect relationships and therefore inform dosing strategies.

**Structure Activity Relationship (SAR):** the relationship between the chemical structure of a molecule (e.g. drug) and the biological activity. Knowledge of SAR can inform the medicinal chemistry strategy to optimise parameters such as potency.

**Boxes**

**BOX 1. Targeting of *Wolbachia* with doxycycline delivers safe curative outcomes in onchocerciasis and lymphatic filariasis**

90% depletion of *Wolbachia* leads to:

* + Arrested development of larval stages
	+ Permanent blockade of embryogenesis
	+ Gradual loss of blood or skin microfilariae
	+ Macrofilaricidal outcomes

Benefit of the anti-*Wolbachia* mode-of-action:

* + Slow kill mechanism avoids side-effects of rapid adult worm death in tissues
	+ Not microfilaricidal
		- de-risks ocular side effects in onchocerciasis
		- Safe to use in *Loa loa* co-infection
	+ Blocks transmission by:
		- permanently sterilising adult worms
		- impairing ability of mf to develop in vectors
	+ Improvement in clinical disease: onchodermatitis, hydrocoele, lymphoedema

**BOX 2:** **Pan-filarial mouse model for preclinical efficacy testing**

**Figure I: Schematic overview of the pan-filarial mouse model**

Advantages of the CB.17 SCID pan-filarial research model:

* + Single small animal host for more accurate interpretation of PK/PD between filarial genera of medical importance (**Figure I**)
	+ Common lab species / strain with historical PK data available
	+ Standardized commercial supply (no breeding costs or management, pedigree strains)
	+ Potential for further technological development: e.g. Humanisation, longitudinal bio-imaging, drug pump implants

**Table 1. Reported efficacy of the two clinical candidates, ABBV-4083 and AWZ1066S compared with approved anti-*Wolbachia* drug, doxycycline, in three filarial infection animal models** [35, 38].

|  |  |  |  |
| --- | --- | --- | --- |
|  | Doxycycline | ABBV-4083 | AWZ1066S |
| *B. malayi*(adult female) | 98.5% *Wolbachia* reductionat 100 mg/kg, qd, 21 days^ | >99% *Wolbachia* reductionat 10 mg/kg, bid, 14 days^ | 97.8% *Wolbachia* reduction;100% mf depletion (peritoneum)at 100 mg/kg, bid, 7 days\* |
| *L. sigmodontis* (adult female) | 0% *Wolbachia* reductionat 40 mg/kg, bid, 14 days^ | 99.7% *Wolbachia* reduction> 99.99% mf depletionat 100 mg/kg, qd, 14 days^ | 99.7% *Wolbachia* reduction> 99.99% mf depletionat 50 mg/kg, bid, 7 days^ |
| *O. ochengi*(adult male) | 99.2% *Wolbachia* reductionat 25 mg/kg, qd, 28 days^# | 98.8% *Wolbachia* reductionAt 75 mg/kg, qd, 14 days^ | N. R. |

^ dosing in jirds; \*dosing in SCID mice; #minocycline; qd once a day; bid twice a day. N. R. none reported.

**Figure 1: The A·WOL screening pipeline.** The current screening assays (shown in light green) have evolved over time and involve *in vitro* assays and *in vivo* pre-clinical models. Movement of compounds through this pipeline is governed by strict go/no-go criteria, highlighted by green arrows, traffic lights and associated text. The chemistry components of the pipeline (shown in blue) feed directly into an iterative process where hits are selected, optimised and re-tested in order to advance the most appropriate for further testing. The incorporation of pharmacokinetic (PK) and pharmacodynamic (PD) analyses (shown in orange) at various points in the pipeline, from determining the PK of initial screening hits to modelling dose prediction, also serves to drive the selection process.

**Figure 2: Anti-*Wolbachia* treatment regimens.** The top half of the figure (purple boxes) illustrates treatment durations (in weeks) determined via clinical trials of tetracycline antibiotics at different doses (100 mg/day or 200 mg/day) with and without albendazole [22, 23, 25, 66, 72]. The bottom half of the figure (green boxes) illustrates predicted regimen reductions with adjusted doses and combinations of registered drugs or novel compounds discovered through the A·WOL consortium [35, 38, 43, 57, 58, 65]. Registered drugs included in the figure are doxycycline (DOXY), minocycline (MINO), rifampicin (RIF), high-dose rifampicin (HD RIF) and albendazole (ALB). Novel compounds shown are ABBV-4083 (TylAMac), AWZ1066S and five chemical clusters identified from high-throughput screening in collaboration with AstraZeneca (AZ 5 CLUSTERS).

**Figure 3: The A·WOL portfolio.** The portfolio of anti-*Wolbachia* compounds/drugs visualised according to their current status in the pipeline, from thousands of screening ‘hits’ through lead series, candidates, ‘proof of concept’ drugs to doxycycline, the only anti-*Wolbachia* drug currently in use. Candidates ABBV-4083 and AWZ1066S, highlighted in bold, are currently progressing through Phase I and Phase II clinical trials. The structures of these candidates are shown.